Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Total Non-current Assets

All assets not expected to be converted to cash within one year.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Total Non-current Assets · Q4 FY2026 · quarter ended Sep 2026

Total non-current assets rises 3.3% from a year ago

Total non-current assets stood at $449.04M at the end of Q4 FY2026, up 3.3% from a year earlier and up 1.9% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.

Context

  • Total non-current assets amounted to 25.8% of total assets at the end of Q4 FY2026, down 5.5 pp from a year earlier.
  • Total non-current assets increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps rising in the next quarterly balance sheet after a +3.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$449.04M+1.9% QoQ
Last fiscal yearSep 2026
$449.04M+3.3% YoY
Year agoSep 2025
$434.66M+3.3% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+3.3%——
3-year CAGR+9.1%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2026
449.04M USD
Year-over-year change
+3.3%
4-year CAGR
+11.9%

Total Non-current Assets vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +3.3% is the 2nd highest of 7, against a peer median of -19.4%.
  • Total non-current assets amounts to 25.8% of total assets for ARWR, versus a peer median of 11.9%.
ARWR Competitors
Total Non-current Assets for ARWR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$938.6M USD+1.8%+2.3%16.9%
IONSIonis Pharmaceuticals, Inc.Sep 2026$551.09M USD+7.2%+17.2%18.9%
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$449.04M USD+3.3%+9.1%25.8%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$28.53M USD-46.2%-14.2%11.6%
WVEWave Life Sciences Ltd.Mar 2026$22.27M USD-26.7%-20.9%3.8%
SLNSilence Therapeutics plcMar 2026$12.27M USD-20.9%+5.7%10.7%
PRQRProQR Therapeutics N.V.Mar 2026€12.06M EUR-17.9%-9.2%12.2%
Peer median (excluding ARWR) —-19.4%-3.4%11.9%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Cash & Equivalents108.01M110.89M102.69M226.55M62.74M
Short-term Investments268.39M292.74M578.28M692.82M1.13B
Net Receivables1.41M006.82M9.93M
Inventory(21.61M)0009.08M
Other Current Assets41.82M7.08M4.97M13.52M45.65M
Total Current Assets405.3M419.52M695.47M950.64M1.29B
Property, Plant & Equipment (Net)168.59M335.56M431.29M426.41M429.65M
Goodwill00000
Intangible Assets11.96M10.26M8.56M6.86M5.16M
Long-term Investments105.87M0007.5M
Tax Assets00000
Other Non-current Assets218K210K4.48M1.39M6.73M
Total Non-current Assets286.64M346.03M444.33M434.66M449.04M
Total Assets691.94M765.55M1.14B1.39B1.74B
Account Payables2.87M35.87M11.39M17.67M30.15M
Short-term Debt2.78M10.56M6.34M40M40M
Tax Payables00000
Deferred Revenue74.1M866K02.4M91.65M
Other Current Liabilities46.86M40.2M63.45M80.43M7.01M
Total Current Liabilities138.85M105.46M103.17M195.49M311.34M
Long-term Debt0268.33M734.54M214.88M838.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)55.95M00021.34M
Other Non-current Liabilities000367.4M400.38M
Total Non-current Liabilities134.75M372.93M845.57M686.39M1.38B
Total Liabilities273.6M478.39M948.74M881.88M1.69B
Common Stock198K200K217K231K237K
Retained Earnings(820.76M)(1.03B)(1.63B)(1.63B)(2.35B)
Accumulated OCI(136K)(3.22M)4.75M6.44M(7.65M)
Other Stockholders Equity00000
Minority Interest19.82M15.82M5.62M37.36M191K
Total Equity418.34M287.16M191.06M503.42M50.5M
Total Debt81.58M383.5M851.91M366.28M1B
Net Debt(26.43M)272.61M749.23M139.74M937.46M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.